BACKGROUND: Elastolysis and ineffective elastogenesis favor the accumulation of tropoelastin, rather than cross-linked elastin, in atherosclerotic plaques. We developed gadolinium-labeled tropoelastin-specific magnetic resonance contrast agents for tropoelastin imaging in animal models.
.02]/s; P=0.001) after administration of the gadolinium-labeled tropoelastin-specific magnetic resonance contrast agent that allowed detection of rupture-prone plaques with high sensitivity (84.4%) and specificity (92.3%). Increased vascular R 1 relaxation rate was observed in carotid endarterectomy plaques after soaking (R 1pre =[1.1±0.26]/s versus R 1post =[3.0±0.1]/s; P=0.01). Ex vivo analyses confirmed the magnetic resonance imaging findings and showed uptake of the contrast agent to be specific for tropoelastin.
Phinikaridou et al; MRI of Tropoelastin in Atherosclerosis C ardiovascular disease accounts for nearly onethird of sudden and premature deaths worldwide. 1 Despite improvements in the management of patients, cardiovascular disease-related deaths are projected to affect 12 million people by 2030. 2 Atherosclerosis is the underlying cause of the majority of cardiovascular events. Atherosclerotic plaque progression involves the dynamic turnover of the extracellular matrix protein, elastin, through elastolysis 3, 4 (degradation) and elastogenesis (de novo synthesis). [5] [6] [7] [8] Elastolysis 3,4 induced by inflammatory processes that upregulate the expression of elastases 9 has been considered the major pathway for elastin remodeling. Conversely, dysfunctional elastogenesis and its contribution to plaque progression and instability are less understood. [5] [6] [7] [8] Elastin is a highly abundant extracellular matrix protein found in the arterial wall that contributes to 50% of its dry weight. 5 Mature elastin is an insoluble and hydrophobic polymer, with a low turnover rate. Mature elastin is formed by cross-linking of tropoelastin, a 60 to 72 kDa soluble monomer, 10 by lysyl oxidase. Mature elastin contains several tropoelastin molecules. Tropoelastin has 2 alternating domains: (1) hydrophilic, cross-linked, domains rich in Lys and Ala; and (2) hydrophobic domains (responsible for elasticity) rich in Val, Pro, and Gly, which often occur in repeats of VPGVG or VGGVG. 10 Endothelial cells, vascular smooth muscle cells, and adventitial fibroblasts produce tropoelastin during the late fetal and early neonatal periods of life, after which elastogenesis ceases. 10 Secreted tropoelastin is chaperoned to the extracellular space by the elastin-binding protein 11, 12 where tropoelastin is stabilized and aligned along microfibrils, that contain glycoproteins (eg, fibrillins) and microfibril-associated glycoproteins (eg, microfibril-associated glycoprotein-1) before enzymatic cross-linking. 13, 14 Thus, normal arteries contain cross-linked elastin but negligible amounts of tropoelastin.
Dysfunctional extracellular matrix synthesis and degradation contribute to the initiation, progression, and complication of arterial diseases, including atherosclerosis, 6, 15, 16 abdominal aortic aneurysm, 17 supravalvular aortic stenosis, 18 in-stent restenosis, 19, 20 and Marfan syndrome. 21 In atherosclerosis, vascular smooth muscle cells 22, 23 and macrophages 6, 8 resume production of tropoelastin that often fails to cross-link into elastic fibers as a result of the reduced expression or absence of lysyl oxidase [24] [25] [26] [27] [28] [29] or any of the components of the microfibrillar scaffold required for fiber assembly. [30] [31] [32] Simultaneously, elastin degradation by elastases 9 generates elastin-derived peptides, including the VGVAPG, that are chemotactic for inflammatory cells, 33 participate in lipoprotein retention, and upregulate matrix metalloproteinases, 5 all of which are involved in the progression and instability of a plaque.
During the past 10 years, there have been significant developments in imaging of molecular components of the vessel wall in vivo. Imaging of vascular elastin has been achieved using the elastin-specific magnetic resonance imaging (MRI) contrast agent (ESMA) 34 in preclinical models of atherosclerosis, [35] [36] [37] abdominal aortic aneurysm, 38 coronary artery injury, 39 and myocardial remodeling after infarction. 40, 41 Collagen-binding paramagnetic nanoparticles have also successfully been used to image collagen remodeling in murine atherosclerosis 42 ; while in vivo optical analysis has been used to quantify changes in collagen and elastin after wall injury. 43 As elastogenesis and elastolysis favor the accumulation of tropoelastin, rather than fully processed crosslinked elastin, we hypothesized that tropoelastin may serve as a new imaging biomarker to detect atherosclerosis progression and lesion instability. Herein, we have developed, characterized, and validated novel tropoelastin-specific MR contrast agents to image tropoelastin turnover in models of atherosclerosis and plaque instability and shown potential to bind to symptomatic plaques taken from patients undergoing carotid endarterectomy.
CLINICAL PERSPECTIVE
A tropoelastin-binding peptide labeled with gadolinium is a novel probe for molecular imaging of dysfunctional elastogenesis by in vivo magnetic resonance imaging. Our new probe combined with quantitative T 1 mapping may be used as a new imaging biomarker to quantify ineffective elastogenesis related to plaque progression and instability and identify plaques that may be susceptible to rupture. Molecular imaging of tropoelastin using our presented imaging approach may provide information on plaque progression and instability and for monitoring the effectiveness of established and novel interventions in different animal models and human tissue. We showed that statins, a widely used intervention, reduced tropoelastin accumulation in atherosclerotic plaques, but the long-term effects on plaque stability remain to be elucidated. Similarly, the effectiveness of novel interventions, that specifically aim elastin remodeling, can be and remain to be investigated using this contrast agent. Importantly, in our work, we implemented magnetic resonance imaging protocols that have already been used in the clinical setting enabling translation of our current findings in bigger animal models of coronary atherosclerosis to identify plaques that may be susceptible to rupture.
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Elastin and Tropoelastin-Binding Probes
The tropoelastin peptides were selected as described in the Methods in the Data Supplement. The probes, (DOTA)-VVGSPSAQDEASPLS and K(DOTA)YPDHVQYTHY, their corresponding scrambled versions DOTA-GAESAPLVSSVQSPD (scrambled-V) and K(DOTA)-HQVYTYPHDY (scrambled-Y), as well as the rhodamine-labeled VVGSPSAQDEASPLS peptide derivative were custom synthesized by Peptide Synthetics Ltd (Hampshire, United Kingdom Synthesis of the lanthanide(III) complexes, in vitro binding, and relaxivity studies were performed as described in the Methods in the Data Supplement.
Murine Model of Atherosclerosis Progression
Male apolipoprotein E knockout (ApoE −/− ) mice and wildtype (WT) C57BL/6J were purchased from Charles Rivers Laboratories (Edinburgh, United Kingdom). Eight-week-old ApoE −/− mice were switched to a high-fat diet (HFD) containing 21% fat from lard and 0.15% (wt/wt) cholesterol (Special Diets Services, Witham, United Kingdom). ApoE −/− mice were imaged at 4, 8, and 12 weeks after HFD feeding (n=10 per group). In the treatment group, ApoE −/− mice (n=10) received pravastatin (40 mg/kg per day; Kemprotec Ltd, Middlesborough, United Kingdom) administered in the drinking water simultaneously with the HFD for 12 weeks. Eight-week-old WT mice (n=10) were fed a normal chow diet for 12 weeks and scanned at 20 weeks.
Rabbit Model of Plaque Instability
Six 3-month-old male New Zealand White rabbits (Harlan, Wyton, England; mean weight, 2.5 kg) were fed a 1% cholesterol diet (Special Diet Services, Witham, England) for 2 weeks before and 6 weeks after balloon injury of the abdominal aorta. This was followed by 4 weeks of normal chow diet as previously described. 36, 44, 45 Diseased rabbits received intraperitoneal administration of Russell's viper venom (0.15 mg/kg; Enzyme Research Laboratories, Swansea, United Kingdom), a procoagulant factor, followed 30 minutes later by intravenous administration of histamine dihydrochloride (0.02 mg/kg; Sigma-Aldrich, Dorset, England), a vasoconstrictor in rabbits, to induce plaque disruption and thrombosis. This procedure was repeated twice within 4 hours. All procedures were approved by the United Kingdom Home Office and were in accordance with institutional guidelines.
Biodistribution of 64 Cu-Labeled Tropoelastin Probes
Biodistribution experiments are described in the Methods in the Data Supplement.
In Vivo Molecular Imaging of Tropoelastin at 3T
All imaging experiments were performed using a 3T Philips Achieva MR scanner (Philips Healthcare, Best, The Netherlands) equipped with a clinical gradient system (30 mT/m, 200 mT/m per millisecond).
Mice
Mice (n=10 per group) were imaged using a single-loop surface coil (diameter=23 mm). The animals were placed in prone position, and the brachiocephalic artery was imaged 30 to 40 minutes post-injection of the tropoelastin-binding contrast agent Gd-TESMA ([Gd-DOTA]-VVGS; 0.2 mmol/kg). A subgroup of animals (n=5 per group) was also scanned 1 hour (optimal time point) after injection of Gd-ESMA (0.2 mmol/kg) on the previous day for comparison (Figure IA in the Data Supplement). In addition, 12 weeks HFD-fed animals (n=3) were imaged 30 to 40 minutes after injection of the scrambled-VVGS probe (0.2 mmol/kg), and another 2 mice were imaged with a 1:1 (Gd-TESMA+La-TESMA) cocktail for in vivo competition experiments. A detailed MRI acquisition protocol is described in the Methods in the Data Supplement.
Rabbits
The abdominal aorta of diseased rabbits was scanned using a 32-channel cardiac coil. Rabbits received general anesthesia and were imaged in a supine position twice before (pre) and 1 time after (post) pharmacological triggering ( Figure  IB in the Data Supplement). The pretrigger MRI included 2 separate scanning sessions: 1 before and after administration of Gd-ESMA and 1 before and after administration of Gd-TESMA. The second MRI session was performed 2 days after the first to allow vessel wall clearance of Gd-ESMA. During these sessions, native zoom T1-weighted blackblood (BB) and delayed-enhanced (DE) images and T1 maps were acquired 2 hours after administration of Gd-ESMA (0.2 mmol/kg) and 40 minutes after administration of Gd-TESMA (0.2 mmol/kg). After the second scan, the rabbits were triggered twice for plaque rupture and the final post-triggering MRI session was performed 8 hours later. The post-trigger MRI included acquisition of native zoom T1-weighted BB images to visualize thrombus. A detailed MRI acquisition protocol is described in the Methods in the Data Supplement.
Ex Vivo T1 Mapping Experiments Using Symptomatic Plaques Taken From Patients Undergoing Carotid Endarterectomy at 3T
Fresh symptomatic carotid endarterectomy specimens were imaged before and after soaking them in Gd-TESMA ( Figure  IC in the Data Supplement). A detailed tissue handling and MRI acquisition protocol are described in the Methods in the Data Supplement. Collection and use of human samples were approved by an institutional review committee, and subjects gave informed consent.
MRI Analysis
In mice, vessel wall area was calculated by manually segmenting the visually enhanced region of the vessel wall as seen on the DE-MRI images using OsiriX (OsiriX Foundation, Geneva, Switzerland). To ensure that the segmented area encompassed the vessel wall, the DE-MRI were coregistered and fused with the magnetic resonance angiography images. T 1 values were computed on a pixel-by-pixel basis using a 3-parameter fit implemented in Matlab. 35 In rabbits, pretrigger native T1-weighted (T1w)-BB images and contrast enhanced inversion recovery and T1 maps were used to assess the vascular remodeling. Post-trigger native T1w-BB images were only used to identify the presence or absence of thrombus as an end point for the classification of plaques as rupture-prone and stable, respectively. The T1 maps were automatically generated after the data acquisition using a 3-parameter fit model. The T1 maps were imported into Osirix, and the vessel wall was manually segmented to calculate the R 1 . When segmenting the T1 maps, the anatomic T1w-BB images were used to aid the identification of the vessel wall contours. The analysis was performed on anonymized data sets in all experiments. T1 maps of ex vivo carotid endarterectomy specimens were analyzed as described above for the rabbit images.
Histology

Mice
The aortic root, aortic arch, brachiocephalic, and carotid arteries were removed en bloc, pinned down to maintain tissue morphology, and fixed in 10% formaldehyde for 48 hours (n=4 per group). Tissues were embedded in paraffin and sectioned transversely (5-μm thick). Verhoeff-Van Gieson elastin staining (HT25A-1KT, Sigma, Dorset, United Kingdom) and Trichrome Stain (Masson) Kit (HT15-1KT, Sigma, Dorset, United Kingdom) were used to investigate vessel wall morphology and elastin and collagen fibers, respectively. Immunohistochemistry for tropoelastin was performed using an anti-mouse rabbit polyclonal antibody (1:100, Abcam, ab21600, Cambridge, MA). Vessel wall area was calculated using the Verhoeff-Van Gieson images as (adventitia area−the luminal area [mm 2 ]) using ImageJ (National Institutes of Health). The immunopositive areas were segmented and expressed as normalized tropoelastin area (%tropoelastin=tropoelastin immunopositive area/vessel wall area)×100. Fluorescent microscopy was performed using a custom-synthesized rhodamine-labeled VVGS peptide derivative (rhod-VVGS). Sections were incubated with a 200 nmol/L solution for 24 hours at 4°C followed by nuclear counterstain using Hoechst (ThermoFischer 33342, 1:3000, for 15 minutes at room temperature). Slides were shielded from light at all times and mounted with a Mowiol containing 2.5% 1,4-diazobicyclo-[2.2.2]-octane (DABCO, Sigma, D2522) medium.
Rabbits
Transverse cryosections (10-μm thick) were collected throughout the length of each segment at 500 μm intervals and stained with Verhoeff-Van Gieson to visualize the elastin fibres and calculate the total elastin content. Immunohistochemistry for tropoelastin was performed using an anti-mouse rabbit monoclonal antibody (1:100, NB100-2076, Novus Biologicals, Abingdon, United Kingdom). Computer-assisted color image analysis (ImageJ) was used to quantify the percentage total elastin and tropoelastin content, using the Verhoeff-Van Gieson elastin and tropoelastin immunohistochemistry stainings, respectively. For registration of the in vivo MRI and histological sections, the distance of the proximal end of each segment from the renal branches and iliac bifurcation, the gross morphology, and internal plaque or thrombus landmarks visible on both the MR and histological images were used as references.
Human Carotid Endarterectomy Specimens
After the imaging experiments, the plaques from endarterectomy were fixed in formalin, decalcified, embedded in paraffin, and sectioned transversely at 5μm. Sections were stained for collagen using Masson trichrome, elastin with VerhoeffVan Gieson, and tropoelastin by immunohistochemistry (1:100, Abcam, ab21600, Cambridge, MA).
Western Blot experiments for quantification of vessel wall tropoelastin concentration are described in the Methods in the Data Supplement.
Inductively coupled plasma mass spectrometry was used to quantify vessel wall gadolinium concentrations as described in the Methods in the Data Supplement.
Statistical Analyses
The detailed statistical methods are described in the Methods in the Data Supplement. P<0.05 was considered statistically significant.
RESULTS
Chemical Structures and In Vitro Binding Assays
The chemical structures and molecular weight of the gadolinium-labeled tropoelastin-binding probes are shown in Figure 1A and 1B.
In vitro binding experiments showed that both K(Eu-DOTA)-YPDH and (Eu-DOTA)-VVGS probes have high selectivity toward tropoelastin compared with other proteins, including collagen I, fibronectin, and HSA (human serum albumin; Figure 1C) . Importantly, the (Eu-DOTA)-VVGS probe showed superior discrimination between tropoelastin and mature elastin (64%±7% versus 1%±2%; P=0.001) compared with K(Eu-DOTA)-YPDH (84%±4% versus 53%±5%; P=0.009). Conversely, Eu-ESMA showed equal binding to tropoelastin and mature elastin (40%±1% versus 41%±2%; P=NS). In addition, both (Eu-DOTA)-VVGS and K(Eu-DOTA)-YPDH did not show binding to HSA, whereas Eu-ESMA has been reported to bind 15% to HSA (value included in Figure 1C 39 ). Finally, Eu-DTPA and complexes of the scrambled VVGS and YPDH probes showed no binding to all proteins studied. The saturation binding plots ( Figure 1D and 1E) showed that both probes bind to tropoelastin whereas no binding to HSA was observed. ·s −1 at 20 MHz, 37°C) 46 ( Figure 2D ) because of the increased molecular weight (reducing the rotational correlation time), which also contributes to second-and outersphere proton relaxation effects. 46 The relaxivity of Gd-ESMA was measured to be 4.9±0.3 (mmol/L)
In the presence of tropoelastin, the relaxivity of the bound fraction was calculated taking into account the K D and a stoichiometry of 1:2 tropoelastin:probe as determined by the fluorescence studies ( Figure 1F ) and was plotted as a function of the magnetic field strength (Figure 2A-2C ). These nuclear magnetic relaxation dispersion profiles correspond to slow tumbling systems with a typical high field peak ≈20 to 40 MHz showing overall higher relaxivity for the tropoelastinbound fraction: 36±1, 44±1, and 25±1 (mmol/L) To investigate the metabolic stability of all Gdprobes, we measured the R 1 relaxation rates of 1 mmol/L solution of the probes incubated with murine and human blood and plasma every 30 minutes, up to 4 hours at 3T. These data showed that the probes were stable in solution for up to 4 hours as the changes in the R 1 relaxation rate were not statistically significant (data not shown).
Biodistribution of 64 Cu-Labeled Tropoelastin Probes
Biodistribution studies showed favorable pharmacokinetics with high renal clearance for both probes and some liver uptake for the K( 
In Vivo Comparison of Vessel Wall Enhancement by MRI Using the Elastin (ESMA) and Tropoelastin Binding (TESMA) Contrast Agent
Considering that (Gd-DOTA)-VVGS was superior in differentiating tropoelastin from cross-linked elastin and had less liver uptake compared with the K(DOTA)-YPDH imaging probe, the (Gd-DOTA)-VVGS, denominated as Gd-TESMA, was selected as the best candidate for in vivo molecular imaging of tropoelastin by MRI. For initial in vivo MRI experiments, control and atherosclerotic ApoE −/− mice were scanned, after the administration of Gd-ESMA, and 24 hours later, after the administration of Gd-TESMA (Figure 3) . Pilot studies showed clearance of Gd-ESMA from both the blood and vessel wall after 24 hours (data not shown). Fused maximum intensity projection magnetic resonance angiography and DE images after injection of Gd-TESMA showed focal uptake in the brachiocephalic artery of an atherosclerotic mouse (Figure 3A) . DE-MRI of the brachiocephalic artery acquired from a control animal after injection of Gd-ESMA showed vessel wall enhancement ( Figure 3B and 3C) as Gd-ESMA binds to endogenously found cross-linked elastin, present in nondiseased arteries. Conversely, there was no enhancement of the control vessel wall after injection of Gd-TESMA because of the lack of tropoelastin in the absence of disease ( Figure 3D and 3E) . However, 2 different atherosclerotic mice showed enhancement of the vessel wall after administration of both Gd-ESMA and Gd-TESMA ( Figure 3F-3M) . DE-MRI showed a larger area of enhancement after administration of Gd-ESMA compared with Gd-TESMA as the diseased vessel wall contains a mixture of cross-linked elastin and tropoelastin and Gd-ESMA binds to both fractions whereas Gd-TESMA only binds to tropoelastin (also see Figure 1C ; Figure IVA and IVB in the Data Supplement).
In vivo molecular MRI of tropoelastin shows accumulation of tropoelastin during atherosclerosis progression in mice. DE-MRI ( Figure 4A 1 -4D 1 and 4A 2 -4D 2 ) and R 1 maps ( Figure 4A 3 -4D 3 ) acquired after administration of Gd-TESMA showed progressive enhancement and increased vessel wall R 1 relaxation rate of the brachiocephalic artery in ApoE −/− mice exposed to an HFD show that the antibody does not bind to endogenously and cross-linked elastin found in the media of control arteries and even in tissues from animals fed with an HFD for 4 weeks. However, as the disease progresses and new tropoelastin fibers are deposited within the growing intima, and also as media elastin becomes fragmented by elastases, the immunopositive areas increase in both of these layers of the vessel wall. ApoE −/− mice fed an HFD for 12 weeks showed less vessel wall enhancement after administration of the scrambled peptide probe (DOTA-GAESAPLVSSVQSPD) compared with those injected with the nonscrambled probe ( Figure 4F 1 -4F 3 ) . In vivo competition experiments showed displacement of the (Gd-DOTA)-VVGS probe by the (La-DOTA)-VVGS probe in the brachiocephalic artery of atherosclerotic mice ( Figure V 
Quantitative MRI, Histology, and Western Blot Measurements of Murine Vessel Wall Tropoelastin
Quantification of the MR data showed that the DE-MRI area ( Figure 5A; Figure 5C ). Quantification of the vessel wall gadolinium concentration by inductively coupled plasma mass spectrometry showed similar trends (control=176±50, 4 weeks=165±38, 8 weeks=244±52, 12 weeks=303±38, statin-treated at 12 weeks=207±23 nmol/g tissue; P=0.007; Figure 5D ). There was a significant correlation between the vessel wall R 1 and gadolinium concentration (r=0.97; P=0.004; 95% CI, 0.69-0.99). A linear regression analysis of average R 1 and average [Gd] per time point of disease progression revealed an in vivo bound relaxivity of r 1 =7.15 (mmol/L) −1 s −1 ( Figure 5E ). We found a significant correlation between the DE-MRI plaque area and vessel wall R 1 measured after administration of Gd-TESMA (r=0.58; P<0.001; 95% CI, 0.46-0.69; Figure 5F ). There were also strong positive correlations between plaque % tropoelastin (measure immunohistochemically) and both the in vivo DE-MRI area (r=0.76; P<0.001; 95% CI, 0.47-0.89; Figure 5G ) and vessel wall R 1 (r=0.93; P<0.001; 95% CI, 0.76-0.96; Figure 5H ), suggesting that the increased MRI signal observed in this model reflects the histological accumulation of tropoelastin fibers within the growing lesion.
In addition to the quantification of tropoelastin by immunohistochemistry ( Figure 5C ), the modulation of the protein levels during atherosclerosis progression and in response to treatment was also measured by Western blotting. Dilutions of recombinant tropoelastin were used to generate a standard curve for the quantification of the tropoelastin concentration from tissue lysates (Figure 5I ). Western blotting of purified cross-linked elastin and soluble tropoelastin showed that the cross-linked polymer gives a high molecular weight band (>250 kDa) whereas the tropoelastin monomer has a molecular weight of 70 kDa ( Figure 5J ). Western blotting of tropoelastin extracted from the vessel wall showed negligible amounts in control arteries and increased deposition during atherosclerosis progression in ApoE −/− mice. Tropoelastin content was decreased in statin-treated ApoE −/− mice ( Figure 5J ). Quantification of tropoelastin concentration in control and diseased arteries is shown in Figure 5K ( 
In Vivo Molecular MRI of Tropoelastin Allows Detection of Rupture-Prone Rabbit Plaque
To test the ability of molecular MRI of tropoelastin in discriminating between stable and rupture-prone plaques, we used a rabbit model of atherosclerosis and controlled plaque rupture. Atherosclerosis was observed at 12 weeks in all 6 injured and cholesterol-fed rabbits, and thrombosis occurred in 5 (83%) animals at rates similar to those previously reported. 36, 44, 45, 47 Figure 6 shows corresponding native T1w-BB, DE images, and T 1 maps after administration of Gd-ESMA and Gd-TESMA acquired at 12 weeks and before triggering for plaque rupture and native T1w-BB images acquired after triggering for plaque rupture.
Representative pretrigger T1w-BB images of a stable ( Figure 6A-6E ) and rupture-prone plaques ( Figure 6G-6K) show the anatomy of the vessel wall and the location of the plaque. The DE images show an enhancement of the vessel wall and shortening of the T1 relaxation time both after the administration of Gd-ESMA and also after the administration of Gd-TESMA. The corresponding T1w-BB images acquired after triggering show the lack of thrombus at the level of the stable plaque and the presence of thrombus at the location of the ruptureprone lesion ( Figure 6F and 6L) . Although both Gd-ESMA and Gd-TESMA lead to vessel wall enhancement, quantitative assessment of the R 1 relaxation rate showed that the uptake of contrast agent was significantly different between stable and rupture-prone lesions only after administration of Gd-TESMA ( Figure 6M ). Ruptureprone plaques uptake significantly more Gd-TESMA compared with stable plaques (R 1 =2.26±0.1 versus R 1 =1.43±0.02; P=0.001) whereas the uptake of Gd-ESMA was similar between stable and rupture-prone plaques (R 1 =2.14±0.05 versus R 1 =2.44±0.07; P=NS). . F, DE-MRI area correlates with vessel wall R 1 measured after administration of Gd-TESMA (n=10 per group). The tropoelastin content measured histologically correlates with both the DE-MRI (G) and vessel wall R 1 relaxation rate (H) measured by MRI after administration of Gd-TESMA (n=4 per group). I, Dilutions of recombinant human tropoelastin were used to generate a standard curve for the quantification of the tropoelastin concentration from tissue lysates using Western blotting. J, Western blotting of purified elastin showed that cross-linked elastin is an insoluble polymer with a high molecular band (>250 kDa) whereas soluble tropoelastin has a molecular weight at 70 kDa. Western blotting for tropoelastin extracted from the vessel wall (n=3 per group) showed negligible amounts in control arteries and increased deposition of the protein during atherosclerosis progression in apolipoprotein E-deficient (ApoE −/− ) mice. Tropoelastin content was decreased in the statin-treated ApoE −/− mice. K, Quantification of tropoelastin concentration in control and diseased arteries as measured by Western blotting.
The sensitivity, specificity, positive predictive value, and negative predictive value of the quantitative assessment of vascular elastin and tropoelastin (R 1 ) after administration of Gd-ESMA and Gd-TESMA, respectively, in detecting the rupture-prone plaque are tabulated in Figure 6N . These measurements suggest that quantitative assessment of vessel wall contrast uptake using T 1 mapping after administration of Gd-TESMA allows better in vivo detection of rupture-prone plaques.
Histological Analyses Show Accumulation of Tropoelastin in Rabbit Rupture-Prone Compared With Stable Plaque
Histological analyses of rabbit sections using Van Gieson elastin showed multiple elastin lamellae consisting of mature, cross-linked elastin in control arteries ( Figure 7A ; black stain), but no corresponding immunopositive tropoelastin fibers suggesting the antibody is specific for monomeric tropoelastin ( Figure 7B and 7C) .
In both stable and ruptured plaques, there was deposition of elastin in the intima ( Figure 7D and 7G) , and in ruptured plaques, there was also additional disintegration and fragmentation of the media elastin as seen by Van Gieson elastin. Immunohistochemistry for tropoelastin (brown stain) showed deposition of tropoelastin in the intima of stable plaque ( Figure 7E and 7F) and a more extensive network of tropoelastin in the intima of ruptured plaque ( Figure 7H and 7I ). In addition, there were immunopositive tropoelastin areas in the media of ruptured plaques that could be because of either deposition of new tropoelastin fibers or exposure of the tropoelastin epitope when mature elastin fibers become fragmented by elastases. Quantification of total elastin and tropoelastin ( Figure 7J and 7K) showed that measuring the tropoelastin accumulation in the vessel wall allowed a better discrimination between stable and ruptured plaques (16.6±3.14 versus 42.2±4.0; P=0.001) compared with measuring the net increase of elastin (28.8%±3.0% versus Figure 6 . In vivo molecular magnetic resonance imaging (MRI) of tropoelastin allows detection of rupture-prone rabbit plaque. Pre-trigger and post-trigger MRI of rabbit stable (A-F) and rupture-prone (G-L) plaques. A and G, Pre-trigger native zoom T1-weighted black-blood (BB) images show the plaque. B, H, C, and I, Delayed-enhanced (DE) inversion recovery images and T 1 maps after administration of Gd-elastin-specific magnetic resonance contrast agent (ESMA) show a strong enhancement of the aortic wall and shortening of the T 1 relaxation time in both stable and rupture-prone plaque. D, J, E, and K, Corresponding delayed-enhanced inversion recovery images after administration of Gd-tropoelastin-specific magnetic resonance contrast agent (TESMA) show vessel wall enhancement and lower T1 values in ruptured-prone compared with stable plaque. F and L, Corresponding native zoom T1-weighted-BB, post-trigger images show the presence of thrombus only at the side of the ruptured plaque. M, Quantification of vessel wall R 1 relaxation rate show a significantly higher R 1 value in rupture-prone compared with stable plaque only after administration of Gd-TESMA. NPV indicates negative predictive value; PPV, positive predictive value. 44 .35%±4.83%; P=0.03) that includes both the crosslinked and non cross-linked elastin fibers. Only negligible amounts of tropoelastin (7.3%±1.45%) were found in control vessel wall segments compared with elastin (26.3%±0.9%).
Ex Vivo Molecular MRI of Tropoelastin in Human Carotid Endarterectomy Samples
To test the translational value of the tropoelastin contrast agent, we performed ex vivo T 1 mapping experiments after soaking the tissues in Gd-TESMA. The MRI results showed retention of Gd-TESMA and significant increase in the R 1 
DISCUSSION
Elastolysis and ineffective elastogenesis favor the accumulation of tropoelastin, rather than mature crosslinked elastin fibers, in atherosclerosis and may trigger plaque progression and instability (6) . We have identified tropoelastin-binding peptides and developed a novel gadolinium-based tropoelastin-binding contrast agent that can be used for MRI of tropoelastin turnover in atherosclerosis. We demonstrate that the newly developed Gd-TESMA probe (Gd-DOTA)-VVGS (1) has high selectivity for tropoelastin, (2) discriminates between tropoelastin and cross-linked elastin, (3) has high in vitro relaxivity (r 1 ) that increases on binding to tropoelastin in solution, and (4) has favorable pharmacokinetics with blood clearance within 1 hour via renal excretion. Using (Gd-DOTA)-VVGS, we demonstrate, for the first time, the feasibility of in vivo imaging of tropoelastin turnover in a murine model of atherosclerotic plaque progression and response to treatment and in a rabbit model of plaque instability. In addition, we show the potential for this novel contrast agent to bind to symptomatic plaques taken from patients undergoing carotid endarterectomy. Molecular imaging of tropoelastin in mice showed increased vessel wall enhancement and R 1 relaxation rates during plaque progression compared with statin-treated and control animals. Histology and Western blotting confirmed the accumulation of tropoelastin within the growing lesion, and inductively coupled plasma mass spectrometry confirmed the accumulation of gadolinium in the vessel wall. Molecular imaging of tropoelastin in rabbits showed significantly higher R 1 relaxation rates in rupture-prone compared with stable lesions showing potential for the detection of high-risk plaques with high sensitivity and specificity. Finally, molecular imaging of human carotid endarterectomy specimens showed detection of intraplaque tropoelastin after soaking the tissues in Gd-TESMA, suggesting that this contrast agent has potential in man. Noninvasive quantification of dysfunctional tropoelas- tin turnover, that fails to cross-link into mature elastin fibres, using a newly developed tropoelastin-binding MR contrast agent, may therefore have diagnostic value in detecting not only plaque progression and response to treatment but also detection of unstable atherosclerotic lesions before plaque rupture.
The main targeted Gd-based low molecular weight contrast agents that have been developed bind to proteins including fibrin (EP-1873 and EP-2104R), 48 collagen (EP-3533 and EP-3600), 49, 50 and elastin (BMS 753951 and LMI 1174) 34, 40, 46 that are highly abundant and thus amenable for MRI. Most of these agents were initially developed as DTPA chelates and then modified to DOTA chelates to increase their thermodynamic and kinetic stability, 48 and all are clear from blood within 1 to 2 hours after injection. Compared with these agents, our new tropoelastin agent with a single Gd-DOTA conjugated to the N-terminal of the 15 amino acid peptide (2 kDa) showed comparable affinity (K D ≈µmol/L), relaxivities, and pharmacokinetics to these agents. 34, 35, 39, [48] [49] [50] Previous studies have shown that the VVGS 11, 12, 51 probe is expected to bind to all sequences that follow the GXXPG and XGXPG motif (where X is a hydrophobic amino acid) that repeats multiple times in the tropoelastin molecule. In murine tropoelastin, these commonly repeated sequences represent 21% of the entire molecule 52 that may explain our observation of higher vessel wall inductively coupled plasma mass spectrometry gadolinium measurements compared with the tropoelastin concentration as measured by Western blotting. The in vivo vessel wall bound relativity of (Gd-DOTA)-VVGS was 7.15 (mmol/L) −1 s −1 , and the image acquisition window lasted up to 1.5 hours post-injection.
As some of the binding sites of tropoelastin might be masked and the amount of water is lower within the atherosclerotic lesion, this could explain why the in vivo bound relaxivity was lower compared with the relaxivity in solution. Future improvements of the chemical properties of the agent, for example, by chelating more Gd 3+ per peptide, or conjugating the peptide to a different chelate unit that enables 2 water molecules in the inner coordination sphere of Gd 3+ could increase the relaxivity of the free, but more importantly of the bound fraction of the agent, and also prolong the imaging acquisition window to allow better detection of vascular tropoelastin and imaging of larger vascular segments.
Our finding that tropoelastin accumulates within the growing lesion and reduces with statin treatment (using immunohistochemistry and Western blotting) in ApoE −/− mice is in agreement with a previous study. 35 Using Western blotting, we found that tropoelastin accumulation is up to 4-fold increased in the murine plaque, compared with control tissue, and reaches a concentration of ≈2 mg/g of tissue. Although statins directly reduce plaque burden through a lipid-lower mechanism, they were also shown to abolish the downregulation of lysyl oxidase produced by tumor necrosis factor-α and low-density lipoprotein particles through a RhoA/Rho kinase-dependent mechanism. 26 Normalization of lysyl oxidase could promote cross-linking of the newly synthesized tropoelastin leading to an overall reduction of tropoelastin, as seen in our study.
When compared with the Gd-ESMA, the new tropoelastin agent resulted in a smaller area of contrast uptake at the same time points by MRI in atherosclerotic ApoE −/− mice. A previous study also reported a higher uptake of ( 153 Gd-DTPA)-ESMA compared with ( 64 Cu-DOTA)-VVGS (13.2% versus 7.2% ID/g). 40 As shown in this and other studies, [35] [36] [37] 39 Gd-ESMA binds equally to cross-linked elastin and tropoelastin. For this reason, enhancement of endogenous cross-linked elastin in nondiseased arteries was also observed in both mice and rabbits. To this end, Gd-ESMA allows measurement of total elastin content and the percentage increase that occurs from the control to the diseased condition by MRI.
In our current study, we found that quantitative assessment of vessel wall contrast uptake using T 1 mapping after administration of Gd-TESMA improved the detection of rupture-prone plaques compared with Gd-ESMA. Rabbit rupture-prone plaques uptake significantly more Gd-TESMA (higher vessel wall R 1 ) compared with stable plaques whereas the uptake of Gd-ESMA was similar between the 2 groups (similar R 1 values). The elimination of signal from endogenously present cross-linked elastin, and detection of only immature tropoelastin, using the Gd-TESMA, agent allowed a stronger discrimination between ruptureprone and stable rabbit plaques and high prediction of unstable lesions compared with Gd-ESMA. In our previous study using the same rabbit model, 36 we showed that administration of Gd-ESMA allowed measurement of plaque burden that was significantly increased in diseased vessel walls (higher R 1 ) compared with control vessels and also improved the assessment of positive vascular remodeling that predicted rupture-prone plaques. Finally, to determine whether tropoelastin could be imaged in human tissue, we performed ex vivo T 1 mapping experiments in carotid plaque samples obtained from endarterectomy and soaked in Gd-TES-MA. The MRI results showed retention of the agent in carotid plaques, and the histological analyses revealed increased levels of tropoelastin in these plaques. Our findings are in agreement with studies demonstrating that synthetic VSCMs 23, 53 and macrophages 6, 8 secrete tropoelastin in rabbit atherosclerotic plaque and human carotid atheroma.
In conclusion, this study shows that the accumulation of tropoelastin is associated with plaque progression and instability in atherosclerotic models. In addition, the novel contrast agent is able to demonstrate the presence in tropoelastin in symptomatic plaques taken from patients supporting a potential role for this novel contrast agent in man.
Study Limitations
Our findings on the value of tropoelastin as a marker of plaque burden and instability rely on the use of animal models of atherosclerosis that reflect, only partly, the complex composition of human atherosclerotic plaques and their evolution toward rupture. Although a small intermediate step of using ex vivo human endarterectomy specimens was used to show the translational potential of our work, future studies including larger numbers of human samples will be needed. In addition, the ability of molecular imaging of tropoelastin to detect rupture-prone plaques was based on a relatively small a number of rabbits, and larger animal studies will be need to confirm these findings.
A potential limitation of our study is that an independent BB (eg, double inversion recovery) sequence for the entire vessel wall anatomy was not acquired for the murine experiments. Instead, we implemented a flow-independent delayed-enhancement MRI protocol that was clinically established for myocardial infarction and coronary vessel wall imaging in humans instead of a flow-dependent BB MRI. Another limitation our study was the lack of an automated/semiautomated software for region-of-interest analysis, which was performed manually for all experiments. Future implementation of threshold-based segmentation algorithms may improve vessel wall segmentation and reduce observer bias. Despite the initial potential of using the tropoelastin agent for imaging human plaques, further optimization and extensive safety checks will be needed before using this agent for in vivo imaging of tropoelastin in man.
Conclusions
We demonstrate the development of a new tropoelastin-binding contrast agent and the first in vivo implementation of molecular imaging of tropoelastin in animal models of plaque progression and instability and show uptake of the agent human carotid plaques ex vivo. Tropoelastin may represent a new imaging biomarker for plaque progression and instability and for the monitoring of the effectiveness of therapeutic interventions. 
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